Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Level 5 - mechanism / opinion, no new human data
narrative review summarizing preclinical mechanisms, veterinary data, and clinical trials
PubMed 27102270 · doi:10.1016/j.preteyeres.2016.04.006
What was done
This narrative review summarizes the role of aldose reductase (AR) and the sorbitol pathway in diabetic ocular complications, including keratopathy, retinopathy, and cataracts. It reviews preclinical animal data, human genetic associations, the outcomes of human clinical trials evaluating diverse AR inhibitors (ARIs), and the development of topical Kinostat for veterinary ophthalmology and prospective human use.
What was found
The abstract reports no primary quantitative data or statistics. It describes a translational gap: while animal models demonstrated that reducing AR flux ameliorated diabetic keratopathy, retinopathy, and cataracts, human clinical trials of ARIs showed limited success or failure in preventing or arresting diabetic retinopathy. Topical Kinostat is highlighted as an emerging therapy for preventing cataracts in diabetic dogs, with speculative future utility for human diabetic keratopathy.
Why it matters
It highlights why systemic aldose reductase inhibitors stalled in human clinical development despite strong preclinical rationale, and outlines a targeted topical strategy for veterinary cataracts with potential translation to human anterior segment disease.
Limits
The abstract provides no primary data, sample sizes, or systematic review methodology. Efficacy claims for Kinostat rely on animal and canine veterinary models; human trials of ARIs for diabetic retinopathy have consistently failed, and human safety and efficacy for Kinostat remain unmeasured.
Cited by
- context Ruth van Heyningen discovered in the 1950s that aldose reductase is expressed at high levels in organs where diabetic complications occur, including the eyes, nerves, blood vessels, and kidneys.
- supports Aldose reductase inhibitors effectively prevent cataractogenesis and treat complications of diabetes in rodent models.